Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives

Triple-negative breast cancer (TNBC) is characterized by the lack of clinically significant levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Owing to the aggressive nature and the emergence of resistance to chemotherapeutic drugs, pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Huimei, Li, Ying, Tan, Yuan, Fu, Shujun, Tang, Faqing, Deng, Xiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170306/
https://www.ncbi.nlm.nih.gov/pubmed/34094935
http://dx.doi.org/10.3389/fonc.2021.648139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170306/
https://www.ncbi.nlm.nih.gov/pubmed/34094935
http://dx.doi.org/10.3389/fonc.2021.648139

Ejemplares similares